Tirzepatide and semaglutide: what is the difference?
Mounjaro and Ozempic are both injected once a week, but they contain different active substances and are not authorised for the same things. This article puts their two product information documents side by side: how each substance works, what each is authorised for, how the dose is built up and which side effects are described. Whether either medicine suits you is a decision for the doctor who reviews your health.
Two active substances, two ways of acting
Mounjaro contains tirzepatide. Its product information describes it as a long-acting agonist of two receptors, GIP and GLP-1, both of which occur in the pancreas, the gut and the areas of the brain involved in appetite. Ozempic contains semaglutide, a GLP-1 analogue that binds to and activates the GLP-1 receptor only.
According to the two documents, semaglutide lowers blood sugar in a glucose-dependent way by stimulating insulin release and lowering glucagon when blood sugar is high, and tirzepatide improves blood sugar control through several mechanisms. Both reduce food intake by acting on appetite, and both delay the emptying of the stomach. Because slower emptying can change how tablets are absorbed, both documents ask for care with some medicines taken by mouth.
What each medicine is authorised for
In the EU, Ozempic has one authorised use: adults with type 2 diabetes that is not well controlled, alongside diet and exercise, either on its own when metformin is unsuitable or added to other diabetes medicines. Weight management is not among its authorised uses. Semaglutide for weight management is authorised separately, under the name Wegovy, with its own product information and its own dose schedule.
Mounjaro has two authorised uses. The first is type 2 diabetes, in adults and in children and adolescents from 10 years of age, on the same terms as above. The second is weight management in adults, alongside a reduced-calorie diet and more physical activity, for people with obesity and for people who are overweight and have at least one weight-related condition, such as high blood pressure, raised blood fats or obstructive sleep apnoea. The body mass index thresholds behind those words are explained on our page on weight loss injections.
Side by side: what the product information says
The table summarises the two product information documents published by the European Medicines Agency. It leaves out study results and anything that is not written in those documents.
| Topic | Mounjaro | Ozempic |
|---|---|---|
| Active substance | Tirzepatide | Semaglutide |
| Receptors it acts on | GIP and GLP-1 | GLP-1 |
| Authorised uses (section 4.1) | Type 2 diabetes in adults and from 10 years of age; weight management in adults | Type 2 diabetes in adults only |
| How it is given | Injection under the skin once a week | Injection under the skin once a week |
| Starting dose (section 4.2) | 2.5 mg once a week for 4 weeks | 0.25 mg once a week for 4 weeks |
| Highest weekly dose | 15 mg in adults; 10 mg in children with type 2 diabetes | 2 mg; higher weekly doses are not recommended |
| Missed dose | Inject within 4 days, otherwise skip it | Inject within 5 days, otherwise skip it |
| Planned pregnancy (section 4.6) | Stop at least 1 month before | Stop at least 2 months before |
| Conditions of supply in the EU (Annex II B) | Subject to medical prescription | On medical prescription |
How the dose is built up
Both medicines start at a low dose that is not meant to be the lasting one, and each later step comes after at least four weeks on the current dose. In the tirzepatide studies, digestive side effects were more frequent while the dose was being raised, and in the semaglutide studies they were reported most often in the first months of treatment. The doctor sets your dose; do not change it on your own, and follow the instructions for use in the leaflet that comes with your pen.
| Step | Tirzepatide (Mounjaro) | Semaglutide (Ozempic) |
|---|---|---|
| Weeks 1 to 4 | 2.5 mg once a week | 0.25 mg once a week |
| After 4 weeks | 5 mg once a week | 0.5 mg once a week |
| Later steps, each after at least 4 weeks | Increases of 2.5 mg if needed | 1 mg, then 2 mg, if needed for blood sugar control |
| Maintenance | 5 mg, 10 mg or 15 mg in adults | 0.25 mg is not a maintenance dose |
| Changing the injection day | At least 3 days between two doses | At least 3 days between two doses |
Taking them with other diabetes medicines
When either medicine is added to metformin or to an SGLT2 inhibitor, both documents say the current dose of those medicines can be continued. When it is added to a sulphonylurea or to insulin, the documents advise considering a lower dose of those medicines to reduce the risk of low blood sugar, and checking your own blood sugar is needed to adjust them. The semaglutide document adds that semaglutide is not a substitute for insulin, so if you take insulin, the doctor needs to know your doses.
Side effects: what is common and what needs attention
In both documents the most frequent side effects are digestive and mostly mild or moderate. For tirzepatide, nausea, diarrhoea and vomiting were more frequent while the dose was being raised and became less frequent over time; for semaglutide these reactions were generally short-lived. The table lists selected side effects by the frequency groups used in section 4.8; the full lists are in the documents.
| How often (section 4.8) | Tirzepatide (Mounjaro) | Semaglutide (Ozempic) |
|---|---|---|
| Very common: at least 1 in 10 people | Nausea, diarrhoea; in the weight management studies also vomiting, abdominal pain and constipation; low blood sugar with a sulphonylurea or insulin in type 2 diabetes | Nausea, diarrhoea; low blood sugar with insulin or a sulphonylurea |
| Common: up to 1 in 10 people | Indigestion, bloating, belching, wind, reflux, dizziness, low blood pressure, hair loss, tiredness, injection site reactions, allergic reactions, raised pancreatic enzymes, faster heart rate | Vomiting, abdominal pain, bloating, constipation, indigestion, gastritis, reflux, belching, wind, reduced appetite, dizziness, headache, tiredness, gallstones, complications of diabetic retinopathy, raised pancreatic enzymes |
| Uncommon: up to 1 in 100 people | Gallstones, inflammation of the gallbladder, acute pancreatitis, delayed stomach emptying, altered taste, injection site pain | Acute pancreatitis, delayed stomach emptying, altered taste, faster heart rate, allergic reactions, injection site reactions |
| Rare or very rare | Anaphylactic reaction, angioedema (rare) | Anaphylactic reaction (rare); NAION, a sudden loss of vision from the optic nerve (very rare) |
Warnings that apply to both
The only contraindication listed in both documents is an allergy to the active substance or to any of the other ingredients. Both documents also warn about acute pancreatitis: if it is suspected, the medicine is stopped, and if it is confirmed, it is not started again. Vomiting and diarrhoea can lead to dehydration and, in some cases, to worse kidney function, so take care to drink enough. Rapid improvement in blood sugar control has been linked with a temporary worsening of diabetic retinopathy, and people with this eye condition need close monitoring.
The semaglutide document also describes NAION; sudden loss of vision needs an eye examination, and semaglutide is stopped if NAION is confirmed. Both documents mention a risk of inhaling stomach contents during general anaesthesia or deep sedation, so tell the team treating you before such a procedure that you use one of these medicines. If you have severe stomach pain, signs of dehydration or a sudden change in your vision, contact a doctor. In an emergency, call 112.
Other medicines, contraception and pregnancy
Because both substances delay stomach emptying, they can change how quickly medicines taken by mouth are absorbed. The tirzepatide document recommends monitoring medicines with a narrow therapeutic index, such as warfarin or digoxin, at the start of treatment and after each dose increase. The semaglutide document recommends frequent INR checks when treatment starts in people who take warfarin or another coumarin anticoagulant.
On the combined pill, the tirzepatide document says that no dose adjustment of oral contraceptives is required, and the semaglutide document says that semaglutide is not expected to reduce their effect. Severe vomiting or diarrhoea can still stop a pill from being fully absorbed, and our page on contraception during weight loss treatment explains what the product information of the pills advises.
Both documents recommend contraception for women who could become pregnant. Semaglutide should not be used in pregnancy and is stopped at least two months before a planned pregnancy; tirzepatide is not recommended in pregnancy and is stopped at least one month before. If you become pregnant, the documents say the medicine should be stopped, so contact a doctor. On breast-feeding they differ: semaglutide should not be used, while the tirzepatide document says it could be considered.
Choosing between them is a medical decision
The doctor starts from what the medicine would be for. Ozempic fits only type 2 diabetes, while weight management is an authorised use of Mounjaro and, for semaglutide, of Wegovy. The doctor also considers your other conditions and medicines, any past pancreatitis or gallbladder problems, diabetic eye disease, pregnancy plans and how you got on with earlier treatment. If you already use one of these medicines, say which one, at what dose and since when; moving from one to the other is the doctor's decision.
For some conditions, and in some individual cases, it is advisable to see a doctor in person; the doctor may recommend this. More about each medicine is on our pages on Mounjaro and Ozempic.
Prescription, pharmacy and cost
If the doctor issues a prescription, you receive it as a PDF by email. You print it and bring it on paper to a pharmacy in Malta together with photo identification. Your prescription is issued in the standard EU cross-border format set out in Directive 2012/52/EU. A pharmacy in Malta may dispense it; the decision rests with the pharmacist. Take the prescription to a pharmacy within six months of the date on it; a prescription for an antibiotic cannot be dispensed more than ten days after its date of issue.
The button on this page shows the fee for the doctor's review of your request. The medicine is a separate cost, and the prescription is a private document. It is not an ePrescription and does not appear in myHealth; it is outside POYC and the Government Formulary List, and you pay for the medicine at the pharmacy in full.
Who reviews your request
Requests are reviewed by Damian Wojno, a doctor registered with the Polish Medical Chamber, licence no. 3211301. The doctor is not registered with the Medical Council of Malta. The doctor reads your medical questionnaire and decides in writing. If the doctor has questions, they ask them in writing in the chat in your account, and you get an email to let you know. There is no video call, no phone call and no live chat. The doctor may ask for records or test results, may recommend that you see a doctor in Malta, and may decline.
Can Ozempic be used for weight loss?
Ozempic is authorised in the EU only for type 2 diabetes in adults, so weight loss is not one of its authorised uses. Semaglutide for weight management is authorised under a different name, Wegovy, and Mounjaro is authorised for type 2 diabetes and, in adults, for weight management. The doctor assesses which of these, if any, fits your situation.
Are Mounjaro and Ozempic the same medicine?
No. Mounjaro contains tirzepatide, which acts on the GIP and GLP-1 receptors, and Ozempic contains semaglutide, which acts on the GLP-1 receptor only. They have different authorised uses, different dose steps and separate product information documents.
Do you need a prescription for Mounjaro or Ozempic in Malta?
Both are authorised centrally for the whole EU, and the conditions of supply in their product information (Annex II B) make both of them medicines on medical prescription. In Malta, all medicines are dispensed only from pharmacies, and the pharmacist decides whether to dispense against a prescription.
What if you miss a weekly dose?
The tirzepatide document says to inject a missed dose as soon as possible within 4 days; after more than 4 days, skip it and inject on your usual day. For semaglutide the limit is 5 days. In both cases you then carry on once a week, and the leaflet in your pack has the full instructions.
How quickly is the dose increased?
Both documents start with a dose that is not meant to last and raise it in steps, each after at least four weeks on the current dose. In the tirzepatide studies, nausea, diarrhoea and vomiting were more frequent while the dose was being increased and became less frequent over time. The doctor sets each step, and you do not change the dose on your own.
- EMA: Mounjaro (tirzepatide) product information, Annex I and Annex II B
- EMA: Ozempic (semaglutide) product information, Annex I and Annex II B
- EMA: Wegovy (semaglutide) product information, section 4.1
- Medicines Authority: prescription-only and non-prescription medicines, validity of prescriptions
- Prescription and Dispensing Requirements Rules (S.L. 458.49), rule 4 (legislation.mt)